For a few years, omega-3 fatty acids were one of the most exciting topics in early-intervention psychiatry. A 2010 randomised trial, led by Paul Amminger and Patrick McGorry in Vienna, suggested that twelve weeks of fish-oil supplementation in young people at very high risk of psychosis cut the rate of conversion to a full psychotic disorder by roughly 75% over the following year. The result, published in Archives of General Psychiatry, was extraordinary — a cheap, almost-side-effect-free supplement seeming to alter the trajectory of one of psychiatry's most serious illnesses.
What happened next is a useful case study in how science actually works.
Omega-3 fatty acids may have a modest role as an adjunct in schizophrenia, but the dramatic early findings on preventing psychosis have not been clearly replicated — the honest summary is "promising, unproven."
The Vienna trial (2010)
Amminger and colleagues recruited 81 young people aged 13 to 25 who met the criteria for "ultra-high risk" of psychosis — meaning they had attenuated psychotic symptoms, brief intermittent psychosis, or a strong family history plus functional decline. Half received 1.2 grams per day of long-chain omega-3 fatty acids (a mix of EPA and DHA) for twelve weeks; half received a coconut-oil placebo. Then the supplements stopped.
By twelve months, only 4.9% of the omega-3 group had developed a full psychotic disorder, compared with 27.5% of the placebo group. A long-term follow-up published in 2015 in Nature Communications reported that the difference persisted for years — even though the active supplementation had only lasted three months. The full study is referenced on PubMed (PMID 20124114).
Why people got excited
Omega-3 fatty acids are integral to neuronal membranes. They influence dopamine and serotonin signalling, reduce neuroinflammation, and are easy to deliver. If a three-month supplement could shift the trajectory of psychosis in vulnerable adolescents, it would be one of the most cost-effective preventive interventions in modern psychiatry. Several centres rushed to test the result.
The NEURAPRO trial (2017)
The largest replication attempt was the international NEURAPRO trial, led by Patrick McGorry himself and published in JAMA Psychiatry in 2017. NEURAPRO enrolled 304 ultra-high-risk young people across multiple countries, randomised them to omega-3 or placebo, and added cognitive behavioural case management for both groups. Result: no significant difference in the rate of transition to psychosis.
The investigators were honest. Their interpretation was that the much higher quality of psychosocial care in NEURAPRO (relative to the original Vienna trial) likely lowered the conversion rate in both groups so much that any omega-3 effect was hard to detect. Other possible explanations: different population characteristics, dose differences, or that the original effect was smaller than the small-trial estimate suggested. The 2017 paper is on the JAMA Psychiatry website.
Where the evidence sits now
- For preventing transition to psychosis in high-risk youth: original trial positive, replication negative. Current early-intervention guidelines do not recommend omega-3 specifically for prevention.
- For add-on treatment in established schizophrenia: meta-analyses (e.g., Fusar-Poli & Berger 2012, several updates since) suggest small benefits for symptoms and quality of life, particularly when EPA dose is at least 2 grams per day and patients are early in the illness. Effects are modest and inconsistent.
- For cardiovascular health in patients on antipsychotics: omega-3 supplementation has reasonable evidence for triglyceride reduction, which is relevant given the metabolic burden of many antipsychotics.
Practical considerations
If you decide to try omega-3 supplementation, a few honest notes:
- Dose matters. Most trials showing benefit used 1 to 3 grams per day of combined EPA + DHA, with EPA usually higher. Standard "fish oil" capsules are often much lower.
- Quality matters. Look for products tested by an independent body (USP, NSF, IFOS). Cheap fish oil can be rancid, which negates much of the benefit.
- Side effects are mild. Fishy burps, occasional GI upset, and a small increase in bleeding tendency at high doses. Tell your surgeon if you are scheduled for surgery.
- Interactions: at typical doses, interactions with antipsychotics are minimal. At high doses, watch for additive bleeding risk if you take blood thinners.
- Food first if possible. Two to three servings per week of oily fish (salmon, sardines, mackerel) is a reasonable baseline. The WHO healthy-diet guidance aligns with this.
Omega-3 supplementation is not a substitute for antipsychotic medication, CBTp, or psychiatric care. The trials that found any benefit used omega-3 as an add-on, never as a replacement.
Why this story is worth knowing
The omega-3 saga is a reminder of two things at once. First, science self-corrects: a striking single result is not a final answer, and the field rightly chased a replication. Second, the absence of a dramatic effect in NEURAPRO does not mean omega-3 has zero role — it means the effect, if it exists, is smaller and more conditional than the original trial suggested. The honest current position is that omega-3s are a low-risk, plausibly mildly helpful adjunct that nobody should expect miracles from.
If you want to add it to your routine
Talk to your prescriber. Many psychiatrists have no objection to a trial of 1 to 2 grams per day of a high-quality EPA-rich fish oil for three to six months, particularly for patients with high triglycerides or significant negative symptoms. If you don't notice anything after that window, it is reasonable to stop.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.